Status:
NOT_YET_RECRUITING
Efficacy & Safety of Oral Adjuvants to Phototherapy in Neonatal Hyperbilirubinemia
Lead Sponsor:
Amira Adel Fouly
Collaborating Sponsors:
Egyptian Chinese University
Ain Shams University
Conditions:
Neonatal Hyperbilirubinemia
Eligibility:
All Genders
1-1 years
Phase:
PHASE4
Brief Summary
Neonatal jaundice, or neonatal hyperbilirubinemia, is a common medical issue in the first two weeks of life, causing prolonged hospitalization and readmissions. It results from elevated total serum bi...
Detailed Description
Neonatal jaundice, or neonatal hyperbilirubinemia, is the most common medical issue in the first two weeks of life and is a frequent cause of prolonged hospitalization and readmission to the hospital ...
Eligibility Criteria
Inclusion
- neonates with both genders
- neonates with gestational age ≥ 32 weeks
- neonates who can tolerate enteral feeding
- diagnosed with unconjugated non-hemolytic hyperbilirubinemia
- Phototherapy is required within the first week of life.
Exclusion
- Neonates with seizures, hydrops fetalis, hypoxic-ischemic encephalopathy, or major congenital anomalies
- Neonates who have had an exchange transfusion within 24 hours
- neonates have evidence of hemolytic causes of jaundice (e.g., ABO and RH
- incompatibility, glucose 6-phosphate dehydrogenase deficiency)
- neonates who have reported hypersensitivity to zinc sulfate or ursodeoxycholic acid.
Key Trial Info
Start Date :
September 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06517862
Start Date
September 1 2024
End Date
December 1 2024
Last Update
August 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neonatal Intensive Care Unit (NICU) of Ain Shams University Hospitals
Cairo, Egypt